Medistem acquires patent-pending rights to potential stem cell treatment for cancer

By Lisa Kerner

Erie, Pa., Feb. 1 - Medistem Laboratories, Inc. said it has acquired exclusive worldwide rights to a potential treatment for cancer that uses stem cells to reprogram malignant cells into benign, non-malignant cells.

The patent pending technology, discovered by Medistem consultant Dr. Thomas Ichim, has the potential to lead to the development of anticancer treatments for a variety of cancers, according to a company news release.

"This new patent pending (technology) strengthens Medistem's intellectual property portfolio," Neil Riordan, Medistem's chief executive officer, said in the release.

"It is an example of the promise of stem cell-based technology to enable the creation of medical therapies that could revolutionize the treatment of cancer and other serious medical conditions."

The patent pending pertains specifically to the use of stem cells derived from adult sources, such as umbilical cords and placentas from healthy, full-term births, according to the release.

The company said published research conducted at Northwestern University with federally approved human embryonic stem cell lines demonstrated the ability of stem cells to successfully reprogram malignant melanoma cells into cells that behave like normal skin cells.

Medistem is a biotechnology company, based in Scottsdale, Ariz., committed to transforming non-controversial adult stem cells into valuable medical treatments.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.